30 closest matches · ranked by relevance
Hepatic Cirrhosis · Liver Fibrosis · Nonalcoholic Fatty Liver Disease (NAFLD)
Primary: The Percentage of Participants Who Achieve a ≥ 1-Stage Improvement in Fibrosis Without Worsening of Nonalcoholic Steatohepatitis (NASH) at Week 48 — 28.2; 24.3; 28.2…
Liver Cirrhosis
Primary: Liver Stiffness by Transient Elastography (FibroScan) — 22.6; 23 kPa
Cirrhosis, Liver
Primary: Enrollment Rate — 20; 20 Participants
Liver Cirrhosis · Hepatic Cirrhosis
Primary: Change From Baseline at Month 3 in cCK18/M30 — 293.5; 257.5; 288.5; 285.0 U/L
Liver Cirrhosis · Portal Hypertension
Primary: Admission Due to Complications Related to Portal Hypertension — 2; 3 participants — p=0.25
Adrenal Insufficiency · Cirrhosis · Spur Cell Anemia
Primary: Number of Participants With Cholesterol Esterification Deficiency — 10; 11 Participants
Fatty Liver, Nonalcoholic · Diabetes Mellitus, Type 2
Primary: Action on Suspected Advanced Liver Fibrosis — 55; 4 Participants
Chronic Liver Disease
Primary: PV Flow — 16.0; 15.5; 23.2; 27.1 ml/s
Liver Cirrhosis
Primary: Number of Participants With Severe Adverse Events — 0; 0; 0 participants
Cirrhosis, Liver
Primary: Number of Participants Attending ≥80% of Intervention Sessions — 16; 5 Participants
Liver Diseases
Primary: Aspartate Transaminase (AST) Change — -6.32 U/L — p=0.03
Portal Hypertension · Chronic Advanced Liver Disease
Primary: Liver Stiffness Measurements for Participants With Compensated Advanced Chronic Liver Disease With and Without Esophageal Varices Upon Esophagogastroduodenoscopy (EGD)…
Cystic Fibrosis · Liver Fibrosis
Primary: Elastographic Value in kPa Measured by Fibroscan — 4.7 kPa
Hepatitis C · Liver Cirrhosis
Primary: AUC 0-∞ — 7240; 24700 h*ng/mL
Cirrhosis · Hepatocellular Carcinoma
Primary: Response (at Least a 50% Reduction in Liver Phospho-EGFR Staining) — 3; 3; 6 Participants
Cirrhosis
Primary: Avoidable Readmission — 23; 12 Number of Avoidable Readmissions
Liver Fibrosis · Cirrhosis · Chronic Hepatitis B
Primary: The Clinical Value Evaluation of FibroTouch for Non-invasive Diagnosis of Liver Fibrosis in Patients With Chronic Hepatitis B by Using Liver Pathology as the Gold…
Liver Cancer
Primary: Proportion of Participants With Successful Control of Disease at 18 Months — .18 proportion of participants
Urea Cycle Disorder
Primary: Liver Stiffness as Measured by Shear Wave Elastography — 13; 14 Participants
Decompensated Cirrhosis and Ascites
Primary: Time to Liver Transplantation or Death Through 1 Year After Randomization: Percentage of Participants With an Event — 33.5; 38.6 percentage of participants — p=0.17
Chronic Liver Disease
Primary: Number of Subjects With Likelihood of Cirrhosis Based on "Hepatic Impairment Score" (HIS) — 146 Participants — p=0.0924
Liver Fibrosis · Nonalcoholic Fatty Liver Disease (NAFLD) · Nonalcoholic Steatohepatitis
Primary: The Percentage of Participants With Improvement in Fibrosis or Nonalcoholic Steatohepatitis (NASH) at Week 24 — 30.6; 24.0; 26.5; 14.3 Percentage of Participants — p=0.055
Liver Cirrhosis
Primary: Number of Participants With Serious Adverse Events Related to Injection — 0 Participants
Hepatic Cirrhosis · Liver Fibrosis
Primary: The Number of Participants Who Achieve ≥ 1 Stage Improvement in Liver Fibrosis (METAVIR Score) as Determined by Liver Biopsy After 12 Weeks of Treatment — 3; 6; 2…
Nonalcoholic Fatty Liver Disease (NAFLD)
Primary: Change in Intrahepatic Lipid Content Between Baseline and 6 Months as Measured by 1H-magnetic Resonance Spectroscopy (1H-MRS). Endpoints Were Assessed at Baseline and 6…
Cirrhosis · Aerobic Exercises · Lifestyle Modification
Primary: Time-domain Heart Rate Variability (HRV) Parameters: SDNN and RMSSD and SDANN — 75.87; 55.13; -4.77; -14.91 milliseconds — p=0.64
Steatotic Liver Disease of Mixed Origin (MetALD)
Primary: Proportion Screened With Alcohol Intake and Weight-related Risks for Metabolism and Alcohol-associated Liver Disease — 26 Participants
Non-alcoholic Fatty Liver Disease
Primary: Hepatic Insulin Sensitivity Index (HISI) — 0.8; 1.4 [10000/(μmol/min)x(mU/L)] — p=<0.019
Hepatocellular Carcinoma
Primary: The Number of Patients in the Cohort Effectively Downstaged to Transplant Eligibility With the LC BeadTM
Ascites · Cirrhosis
Primary: Number of Participants With Worsening Ascites (Increase in Number of Paracentesis Procedures to Remove 2 Liters of Ascites Fluid) — 0 participants